^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Eye Cancer

Related cancers:
1d
One hotspot RB1 mutation disrupt RB1 function founded in a Chinese patient. (PubMed, Front Oncol)
Furthermore, our results highlight the importance of offering targeted genetic testing and counseling to families with RB1 mutations. The identification of the somatic origin of this mutation was vital in ruling out the heritability of this condition in this specific patient.
Journal
|
RB1 (RB Transcriptional Corepressor 1)
|
RB1 mutation
1d
GNAQ Induces Melanomagenesis in Mitfa-Independent Melanocyte Progenitors in a Zebrafish Model of Uveal Melanoma. (PubMed, Cancer Res)
Analogous PAX3 positive populations were also identified in mouse and human single-cell transcriptomic datasets. Collectively, these findings establish a critical role for Mitfa-independent melanocyte progenitors in UM pathogenesis.
Journal
|
GNAQ (G Protein Subunit Alpha Q) • FN1 (Fibronectin 1) • PAX3 (Paired Box 3)
|
BRAF V600E
2d
Context-dependent roles of lncRNA JPX in human cancers. (PubMed, Discov Oncol)
JPX should not be regarded as a uniformly oncogenic lncRNA. Its role appears to depend on tumor context, the dominant downstream program, and, in some settings, the status of the JPX-XIST axis. JPX is better viewed as a candidate biomarker and an experimental target than as a clinically validated one.
Review • Journal
|
XIST (X Inactive Specific Transcript)
3d
Identification and validation of prognostic genes related to centrosome amplification in multiple myeloma. (PubMed, PeerJ)
RT-qPCR validation confirmed a significant up- regulation of these six genes in MM. Six prognostic genes associated with CA in MM were identified, and a predictive risk model was developed, offering valuable insights for clinical prognosis and immunotherapy in MM.
Journal • IO biomarker
|
CCND1 (Cyclin D1) • ARL2 (ADP Ribosylation Factor Like GTPase 2) • RUVBL1 (RuvB Like AAA ATPase 1)
3d
New P1/2 trial • First-in-human
4d
BIRC5 drives cell-cycle dysregulation and represents a novel molecular target in retinoblastoma. (PubMed, Front Oncol)
Conversely, BIRC5 knockdown induced G1 cell cycle arrest and increased apoptotic activity, accompanied by activation of checkpoint pathways. This study defines BIRC5 as a cell-state-specific regulator of malignant proliferation in retinoblastoma and provides a mechanistic rationale for targeting survivin in highly proliferative tumor subpopulations.
Journal
|
RB1 (RB Transcriptional Corepressor 1) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CHEK2 (Checkpoint kinase 2) • BIRC5 (Baculoviral IAP repeat containing 5) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
7d
Non-Genetic Mechanisms of Fractional Resistance to Abemaciclib in Dedifferentiated Liposarcoma. (PubMed, bioRxiv)
Dedifferentiated liposarcoma is a rare mesenchymal malignancy driven by amplification of chromosome 12q13-15, which includes the oncogenes CDK4 and MDM2. These fractionally resistant cells were defined by selective enrichment of cyclin-dependent kinase 2 (CDK2), cyclin B1, and phosphorylated ribosomal protein S6 (pS6), and showed enhanced sensitivity to the CDK2 inhibitor, tagtociclib. Together, these findings reveal nongenetic cell cycle plasticity as a mechanism of escape from CDK4/6 inhibition in dedifferentiated liposarcoma and nominate CDK2 and the PI3K-mTOR pathway as candidate targets for combination therapy.
Journal
|
MDM2 (E3 ubiquitin protein ligase) • CCNB1 (Cyclin B1)
|
Verzenio (abemaciclib) • tegtociclib (PF-07104091)
7d
Efferocytosis induces proangiogenic function and chromatin remodeling in tumor-associated macrophages. (PubMed, Sci Immunol)
In human uveal melanoma, expression of the effero-score was correlated with poor survival. Therefore, Effero-seq sheds light on the molecular reprogramming induced by efferocytosis in the TME, opening previously unknown avenues for understanding macrophage function and developing targeted treatments.
Journal
|
IFNG (Interferon, gamma)
7d
Growth hormone-secreting adenoma with lack of retinoblastoma protein expression. (PubMed, JCEM Case Rep)
Although mice with Rb1 gene inactivation invariably develop pituitary adenomas, and some evidence suggests that a subset of pituitary adenomas have lack or reduced expression of Rb protein, to date no evidence has been reported that patients with germline mutations in the RB1 gene (that encodes for Rb protein) are at risk of developing pituitary adenomas. Here, we report the case of a patient with childhood (age 1 year) onset retinoblastoma because of a germline pathogenic variant of the RB1 gene who presented with a somatotropinoma diagnosed at a young age (20) and whose pituitary adenoma cells showed loss of expression of Rb protein by immunohistochemistry, suggesting a role of Rb in preventing the development of pituitary adenomas.
Journal
|
RB1 (RB Transcriptional Corepressor 1)
|
RB1 mutation
8d
Types of phacomatosis pigmentovascularis associated with nevus cesius. (PubMed, Acta Dermatovenerol Alp Pannonica Adriat)
A high frequency of NA and the Klippel-Trénaunay phenotype (or leg-length discrepancy) was observed in phacomatosis melanocesioflammea. The existence of "pseudodidymosis cesioanemica" is also corroborated.
Review • Journal
|
GNAQ (G Protein Subunit Alpha Q) • GNA11 (G Protein Subunit Alpha 11)
8d
Magnetic resonance imaging features of RB1-deleted adipocytic neoplasms in a survivor of bilateral retinoblastoma. (PubMed, Pediatr Radiol)
Survivors of hereditary retinoblastoma, caused by germline mutations in the RB1 gene, have a substantially increased risk of developing benign and malignant lipomatous tumors including atypical spindle cell/pleomorphic lipomatous tumor and dysplastic lipoma. This report describes the MRI findings of several such lesions in a survivor of bilateral retinoblastoma including features such as enhancement that might otherwise be concerning for higher-grade malignancy.
Journal
|
RB1 (RB Transcriptional Corepressor 1)
|
RB1 deletion • RB1 mutation